NCT02389231 (ANEMIL) is a Phase 1, PHASE2 clinical trial of Interleukine-2 in Autoimmune Hemolytic Anemia, sponsored by University Hospital, Bordeaux.

Who is sponsoring NCT02389231?

NCT02389231 is sponsored by University Hospital, Bordeaux.

What drugs are being tested in NCT02389231?

Interventions in NCT02389231: Interleukine-2.

What condition does NCT02389231 study?

NCT02389231 studies Autoimmune Hemolytic Anemia.

Is NCT02389231 still recruiting?

NCT02389231 is currently completed. Last updated 18 February 2019.

Last reviewed 2019-02-18 · How we verify

NCT02389231: ANEMIL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment

Completed Phase 1, PHASE2 Last updated 18 February 2019

What this trial tests

Phase 1, PHASE2 trial testing Interleukine-2 in Autoimmune Hemolytic Anemia in 2 participants. Completed in 16 November 2018.

Timeline

17 May 2017

Primary endpoint
16 November 2018

16 November 2018

Quick facts

Lead sponsor	University Hospital, Bordeaux
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	17 May 2017
Primary completion	16 November 2018
Estimated completion	16 November 2018
Sites	1 location across France

Drugs / interventions tested

Interleukine-2 — full drug profile →

Conditions studied

Autoimmune Hemolytic Anemia — all drugs for Autoimmune Hemolytic Anemia →

Sponsor

University Hospital, Bordeaux

Who can join

18 and older, any sex, with Autoimmune Hemolytic Anemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators have demonstrated that the mean percentage of circulating CD8+ regulatory T (CD8 Tregs) cells is significantly higher in patients with warm hemolytic anemia (wAHAI) in remission than in controls and is correlated to hemoglobin levels. In vitro, low dose of interleukine-2 (IL2) induce the expansion of CD8 Tregs. The objective is to demonstrate that, over a 9 week treatment period; low doses of IL2 can induce the expansion of CD8Tregs in patients with active wAHAI.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Autoimmune hemolytic anemia: current knowledge and perspectives.
Michalak SS, Olewicz-Gawlik A, Rupa-Matysek J, Wolny-Rokicka E, et al · · 2020 · cited 72× · PMID 33292368 · DOI 10.1186/s12979-020-00208-7
The EHA Research Roadmap: Anemias.
Iolascon A, Rivella S, Anagnou NP, Camaschella C, et al · · 2021 · cited 7× · PMID 34522846 · DOI 10.1097/hs9.0000000000000607

Verify or expand the search:

Other recruiting trials for Autoimmune Hemolytic Anemia

Currently open trials in the same condition.

NCT07441525 — UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases · EARLY_PHASE1 · recruiting
NCT07175493 — A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia · Phase 1, PHASE2 · recruiting
NCT06921980 — Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia · recruiting
NCT06733610 — CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy. · Phase 1 · recruiting
NCT06888960 — Safety Study of CC312 in Autoimmune Disease Patients · EARLY_PHASE1 · recruiting

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02389231 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
Last refreshed: 18 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02389231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing